Yiying Gao

Yiying Gao

Auto-generated profile, based on publicly available information

Yiying Gao

Sichuan Center for Disease Control and Prevention

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
YQYuyou Qiu
Yuyou Qiu
YGYiying Gao
Yiying Gao
DYDaojiang Yu
Daojiang Yu
LZLi Zhong
Li Zhong
WCWeichao Cai
Weichao Cai
SZShuyu Zhang
Shuyu Zhang

1 July 2020 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
ZWZhenyu Wang
Zhenyu Wang
WSWenhao Shen
Wenhao Shen
XLXugang Li
Xugang Li
YFYang Feng
Yang Feng
KQKun Qian
Kun Qian
JCJianping Cao
Jianping Cao
Purpose: As radiation therapy is widely used for the management of pancreatic cancer, identifying novel targets to improve the radiosensitivity of cancer cells is beneficial. Rosiglitazone, a specific peroxisome proliferator-activated receptor γ (PPARγ) agonist, has an inhibitory effect on various types of cancer cells. The purpose of this paper is to investigate the effect of rosiglitazone on the radiosensitivity of pancreatic cancer cells and the potential mechanism. Materials and Methods: PPARγ expression in pancreatic cancer and adjacent tissues was evaluated using immunohistochemistry analysis. The viability, migration and invasion ability of PANC1 and PaTu8988 cells were detected using MTT assay, scratch-wound assay and transwell invasion assay. The effect of rosiglitazone on radiosensitivity of the cells was determined using the clonogenic assay. PANC1 cells were inoculated into BALB/c mice to establish tumors. Microarray was used to investigate changes of genes involved. Results: Higher PPARγ expression was demonstrated in pancreatic cancer tissues compared with para-carcinoma tissues. Rosiglitazone inhibited the cell viability and enhanced the radiation-induced anti-migration and anti-invasion effect. Rosiglitazone potentiated the radiosensitivity of pancreatic cancer cells and PANC1 xenografts. Microarray analysis revealed that rosiglitazone plus radiation altered the expression of multiple genes and affected multiple pathways. Conclusion: Rosiglitazone enhances the radiosensitivity of human pancreatic cancer cells in vitro and in vivo via complex mechanisms.

23 July 2026 in Dose-Response
Verified
Journal Article
Open access
YGYiying Gao
Yiying Gao
HWHaoyu Wang
Haoyu Wang
LHLing He
Ling He
LHLiangguo He
Liangguo He
WWWantian Wang
Wantian Wang
DLDeming Liu
Deming Liu
Accurate dose estimation following radiation accidents remains challenging, particularly when personal dosimeter data are unavailable. This study presents a practical post-accident dose reconstruction approach based on minute-rate thermoluminescent dosimeter (TLD) measurements combined with exposure scenario reconstruction, demonstrated through a wavelength-dispersive X-ray fluorescence (WD‒XRF) spectrometer accident. The exposure scenario was reconstructed by placing LiF(Mg,Cu,P) TLDs at seven representative positions corresponding to head and hand locations, with the spectrometer operated under the recorded technical parameters (40 kV, 7 mA). Minute personal dose equivalent rates, H p ′(10), were measured and combined with reconstructed retention times to calculate cumulative doses, from which skin absorbed doses were derived. The measured dose rates ranged from 0.13 to 358.38 mSv/min for the head and from 0.07 to 620.24 mSv/min for the hands. The resulting cumulative skin absorbed doses were 7.58 Gy for the head and 12.52 Gy for the hands, consistent with reported dose ranges associated with localized radiation injury. This approach provides a feasible supplementary strategy for retrospective dose reconstruction under emergency or resource-limited conditions when conventional dosimetric information is unavailable.